EIF2AK4

Across TCGA pan-cancer cohorts, EIF2AK4 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of EIF2AK4’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where EIF2AK4 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types EIF2AK4 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where EIF2AK4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EIF2AK4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.122	<.001	9	view →
HNSC	All	IV	+0.256	<.001	8	view →
LSCC	Female	All	+0.189	<.001	7	view →
PDAC	Female	III,IV	−0.238	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

EIF2AK4–CCRCC

Open the CCRCC breakdown →